Gene Therapy Shows Promise in Weight Loss and Blood Sugar Control, Early Research Suggests

Researchers are exploring novel gene therapy approaches that have demonstrated significant weight loss and improved blood sugar regulation in preclinical studies, potentially offering a new avenue for treating obesity and diabetes.

Early research, including studies conducted at Duke University, indicates higher-than-expected production of glucagon-like peptide-1 (GLP-1) in alpha cells from human pancreatic tissue. Several companies are now pursuing methods to boost GLP-1 production directly within the body. Fractyl Health is developing a gene therapy, dubbed “Rejuva,” that utilizes a viral vector to deliver DNA instructions to pancreatic cells, prompting them to produce GLP-1. In mouse models, Rejuva reportedly led to approximately 20% weight loss within three weeks, and normal-weight mice maintained healthy blood sugar levels even when fed a high-fat diet.

“It outperformed semaglutide,” stated Harith Rajagopalan, cofounder and CEO of Fractyl Health, in a recent interview. The Rejuva approach involves a small virus delivering the necessary DNA instructions directly to cells, with Rajagopalan expressing confidence in its potential safety due to the anticipated low dosage. Another company, RenBio, is taking a different tack, injecting DNA instructions for GLP-1 production via a saline solution and using electrical pulses to deliver them into cells, effectively turning cells into “protein factories.” This method resulted in roughly 15% weight loss in mice, with the weight loss sustained for at least a year, alongside improved blood sugar control. GLP-1 is a naturally occurring hormone that helps regulate appetite and blood glucose levels; medications like semaglutide mimic its effects, but these new therapies aim for a more permanent solution.

Experts caution that these gene therapy approaches, if applied to humans, could be irreversible and potentially lead to long-term pancreatic issues. Further research and clinical trials are necessary to assess the safety and efficacy of these methods in humans. Officials stated that the next phase will involve rigorous safety testing and careful monitoring of long-term effects.